Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
54 hedge funds and large institutions have $379M invested in Inozyme Pharma in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 10 closing their positions.
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
8.8% more ownership
Funds ownership: 69.77% → 78.57% (+8.8%)
2% more funds holding
Funds holding: 53 → 54 (+1)
11% less capital invested
Capital invested by funds: $428M → $379M (-$48.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$5.11M |
| 2 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
+$4.07M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.19M |
| 4 |
BlackRock
New York
|
+$3.09M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.16M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.24M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.18M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$633K |
| 5 |
CA
CHI Advisors
New York
|
-$327K |
INZY Hedge Fund Activity: Q4 2020 in Review
54 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q4 2020, worth a combined $379M — down 11% from $428M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new INZY positions and 10 closed out — a net gain of 1 holder — while 20 added to existing stakes and 7 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $5.11M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.16M sold.
- 54 institutional investors held Inozyme Pharma (INZY) as of Q4 2020, up from 53 in Q3 2020.
- Funds reported $379M of Inozyme Pharma stock for Q4 2020, down 11% quarter-over-quarter.
- 11 funds opened new Inozyme Pharma positions in Q4 2020 and 10 closed out, a net change of +1 holder.
- The largest Inozyme Pharma buyer in Q4 2020 was Suvretta Capital Management, an estimated $5.11M added.
- The largest Inozyme Pharma seller in Q4 2020 was Sphera Funds Management, an estimated $5.16M sold.
Based on aggregated 13F filings for Q4 2020.